Payment overview · 2025
General Payments
$402.18
22 reported records · 12 companies
Healthcare provider profile · identity verified
Benjamin C Mozie, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSONVILLE, NC · NPI 1639195019
Verified facts
What the public records show
CMS Open Payments records show Benjamin C Mozie, MD received $402.18 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.50 | 18.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $70.63 | 17.6% | 4 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $55.44 | 13.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.66 | 11.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.66 | 8.4% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.52 | 6.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.36 | 5.1% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.66 | 4.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.46 | 4.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.65 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.47 | 3.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.17 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $402.18 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $70.63 | 4 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $55.44 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.66 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $41.32 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.18 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 58 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 166 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
166 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
128 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 506 | 133 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 320 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 59 |
| Losartan Potassium | Losartan Potassium | 259 | 71 |
| Furosemide | Furosemide | 242 | 51 |
| Metformin Hcl | Metformin Hcl | 242 | 53 |
| Gabapentin | Gabapentin | 216 | 51 |
| Ibuprofen | Ibuprofen | 170 | 56 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 166 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 152 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 151 | 21 |
| Omeprazole | Omeprazole | 145 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 144 | 36 |
| Meloxicam | Meloxicam | 144 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 34 |
| Trulicity | Dulaglutide | 128 | 19 |
| Azithromycin | Azithromycin | 127 | 74 |
| Jardiance | Empagliflozin | 126 | 31 |
| Glipizide | Glipizide | 120 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 120 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 110 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 21 |
| Lisinopril | Lisinopril | 101 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 19 |
| Allopurinol | Allopurinol | 94 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 28 |
| Potassium Chloride | Potassium Chloride | 84 | 21 |
| Trazodone Hcl | Trazodone Hcl | 83 | 16 |
| Amoxicillin | Amoxicillin | 82 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 18 |
| Lorazepam | Lorazepam | 76 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 74 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 72 | 13 |
| Januvia | Sitagliptin Phosphate | 71 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 69 | suppressed |
| Nifedipine Er | Nifedipine | 67 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 12 |
| Sertraline Hcl | Sertraline Hcl | 67 | 16 |
| Simvastatin | Simvastatin | 67 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | suppressed |
| Carvedilol | Carvedilol | 58 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 12 |
| Eliquis | Apixaban | 58 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 14 |
| Alprazolam | Alprazolam | 54 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 11 |
| Metformin Hcl Er | Metformin Hcl | 44 | 14 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 16 |
| Ozempic | Semaglutide | 43 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Prednisone | Prednisone | 42 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 12 |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Famotidine | Famotidine | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 12 |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Nystatin | Nystatin | 35 | 13 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 25 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Motegrity | Prucalopride Succinate | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $402.18 · 22 records | ABBVIE INC. | AIRSUPRA, AREXVY, CONTRAVE, ELIQUIS, GVOKE HYPOPEN, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, REXULTI, Senza, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error